- Hepatobiliary and Splenic Surgery Ward of Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China;
ObjectiveTo summarize the current status and the management of colorectal cancer liver metastases (CRCLM) in the elderly and to explore the therapeutic principles and methods. MethodsForeign and domestic literatrues on management of CRCLM were reviewed and analyzed. ResultsColorectal cancer was still one of the most common malignancy and the most common site for metastasis was liver. In the past years, the incidence of colorectal cancer in the elderly was gradually going up. A similar outcome can be achieved for the appropriate elder metastasis patients compared to the young group, although they were in worse physical conditions. Surgical resection was still the only possible treatment for cure to the resectable CRCLM, chemotherapy and biological therapy were also valuable adjunct therapies. For unresectable liver metastases, alternative treatments were recommended, such as radiofrequency ablation and hepatic artery infusion, etc. ConclusionAccording to the characteristic of CRCLM and the physical features of the eldrly patients, a better outcome should be obtained through multipledisciplinary individualized therapy.
Citation: JIA Changjun,DAI Chaoliu.. Management of Colorectal Cancer Liver Metastases in The Elderly. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2011, 18(5): 485-493. doi: Copy
1. | Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [J]. CA Cancer J Clin, 2010, 60(5): 277300. |
2. | 张思维, 雷正龙, 李光琳, 等. 中国肿瘤登记地区2006年肿瘤发病和死亡资料分析 [J]. 中国肿瘤, 2010, 19(6): 356365. |
3. | 中华医学会外科学分会胃肠外科学组、结直肠肛门外科学组, 中国抗癌协会大肠癌专业委员会. 结直肠癌肝转移诊断和治疗指南(V 2010) [J]. 中华胃肠外科杂志, 2010, 13(6): 457470. |
4. | NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Colon Cancer. Version 3.2011. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. |
5. | Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view [J]. Semin Liver Dis, 1984, 4(2): 170179. |
6. | Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment [J]. Ann Surg, 1984, 199(5): 502508. |
7. | Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases [J]. Br J Surg, 2010, 97(7): 11101118. |
8. | Ito K, Govindarajan A, Ito H, et al. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century [J]. Cancer J, 2010, 16(2): 103110. |
9. | Tsim NC, Frampton AE, Habib NA, et al. Surgical treatment for liver cancer [J]. World J Gastroenterol, 2010, 16(8): 927933. |
10. | Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 19952007: an analysis of populationbased cancer registry data [J]. Lancet, 2011, 377(9760): 127138. |
11. | 中华人民共和国国家统计局. 2010年第六次全国人口普查主要数据公报(第1号). http://www.stats.gov.cn/tjfx/jdfx/t20110428_402722253.html. |
12. | 杜鹏, 翟振武, 陈卫. 中国人口老龄化百年发展趋势 [J]. 人口研究, 2005, 29(6): 9093. |
13. | Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part Ⅰ [J]. Cancer J, 2005, 11(6): 449460. |
14. | NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Senior Adult Oncology. Version 2.2011. http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. |
15. | Pallis AG, Papamichael D, Audisio R, et al. EORTC Elderly Task Force experts’ opinion for the treatment of colon cancer in older patients [J]. Cancer Treat Rev, 2010, 36(1): 8390. |
16. | Brand MI, Saclarides TJ, Dobson HD, et al. Liver resection for colorectal cancer: liver metastases in the aged [J]. Ann Surg, 2000, 66(4): 412415, discussion 415416. |
17. | Zacharias T, Jaeck D, Oussoultzoglou E, et al. First and repeat resection of colorectal liver metastases in elderly patients [J]. Ann Surg, 2004, 240(5): 858865. |
18. | Nagano Y, Nojiri K, Matsuo K, et al. The impact of advanced age on hepatic resection of colorectal liver metastases [J]. J Am Coll surg, 2005, 201(4): 511516. |
19. | Menon KV, AlMukhtar A, Aldouri A, et al. Outcomes after major hepatectomy in elderly patients [J]. J Am Coll Surg, 2006, 203(5): 677683. |
20. | Figueras J, Ramos E, LopezBen S, et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? [J]. Clin Transl Oncol, 2007, 9(6): 392400. |
21. | Mazzoni G, Tocchi A, Miccini M, et al. Surgical treatment of liver metastases from colorectal cancer in elderly patients [J]. Int J Colorectal Dis, 2007, 22(1): 7783. |
22. | Wang X, Hershman DL, Abrams JA, et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis [J]. Br J Cancer, 2007, 97(12): 16061612. |
23. | de LiguoriCarino N, van Leeuwen BL, Ghaneh P, et al. Liver resection for colorectal liver metastases in older patients [J]. Crit Rev Oncol Hematol, 2008, 67(3): 273278. |
24. | Mann CD, Neal CP, Pattenden CJ, et al. Major resection of hepatic colorectal liver metastases in elderly patients - an aggressive approach is justified [J]. Eur J Surg Oncol, 2008, 34(4): 428432. |
25. | Bockhorn M, Sotiropoulos GC, Sgourakis G, et al. Major liver resections in the elderly-is an aggressive approach justified? [J]. Int J Colorectal Dis, 2009, 24(1): 8386. |
26. | Nojiri K, Nagano Y, Tanaka K, et al. Validity of hepatic resection of colorectal liver metastases in the elderly (75 years and older) [J]. Anticancer Res, 2009, 29(2): 583588. |
27. | Tamandl D, Gruenberger B, Herberger B, et al. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients [J]. J Surg Oncol, 2009, 100(5): 364371. |
28. | Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases: a national experience [J]. Cancer, 2009, 15(4): 752759. |
29. | Rees M, Tekkis PP, Welsh FK, et al. Evaluation of longterm survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients [J]. Ann Surg, 2008, 247(1): 125135. |
30. | Reddy SK, Barbas AS, Turley RS, et al. Major liver resection in elderly patients: a multiinstitutional analysis [J]. J Am Coll Surg, 2011, 212(5): 787795. |
31. | 蔡三军. 结直肠癌肝转移的治疗现状 [J]. 中华胃肠外科杂志, 2009, 12(4): 430431. |
32. | Thelen A, Jonas S, Benckert C, et al. Simultaneous versus staged liver resection onf synchronous liver metastasis from colorectal cancer [J]. Int J Colorectal Dis, 2007, 22(10): 12691276. |
33. | 涂玉亮, 焦华波, 谭向东, 等. 70岁以上老年患者结直肠癌肝转移同步手术切除的临床分析 [J]. 中国急救复苏与灾害医学杂志, 2010, 5(8): 734736, 744. |
34. | Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after twostage resection of advanced colorectal liver metastases: responsebased selection and complete resection define outcome [J]. J Clin Oncol, 2011, 29(8): 10831090. |
35. | Wicherts DA, Miller R, de Haas RJ, et al. Longterm results of twostage hepatectomy for irresectable colorectal cancer liver metastases [J]. Ann Surg, 2008, 248(6): 9941005. |
36. | Karoui M, Viqano L, Goyer P, et al. Combined firststage hepatectomy and colorectal resection in a twostage hepatectomy strategy for bilobar synchronous liver metastases [J]. Br J Surg, 2010, 97(9): 13541362. |
37. | Mohammad WM, Balaa FK. Surgical management of colorectal liver metastases [J]. Clin Colon Rectal Surg, 2009, 22(4): 225232. |
38. | de Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastases: results from an international multiinstitutional analysis [J]. J Gastrointest Surg, 2009, 13(12): 21412151. |
39. | Sa Cunha A, Laurent C, Rault A, et al. A second liver resection due to recurrent colorectal liver metastases [J]. Arch Surg, 2007, 142(12): 11441149. |
40. | de Liquori Carino N, van Leeuwen BL, Ghaneh P, et al. Liver resection for colorectal liver metastases in older patients [J]. Crit Rev Oncol Hematol, 2008, 67(3): 273278. |
41. | Adam R, Bhanqui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? [J]. Ann Surg, 2010, 252(5): 774787. |
42. | Nordlinger B, Van Cutsem E, Rouqier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group [J]. Eur J Cancer, 2007, 43(14): 20372045. |
43. | Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage Ⅳ colorectal cancer receiving combination chemotherapy without surgery as initial treatment [J]. J Clin Oncol, 2009, 27(20): 33793384. |
44. | Costi R, Di Mauro D, Giordano P, et al. Impact of palliative chemotherapy and surgery on management of stage Ⅳ incurable colorectal cancer [J]. Ann Surg Oncol, 2010, 17(2): 432440. |
45. | Costi R, Di Mauro D, Veronesi L, et al. Elective palliative resection of incurable stage Ⅳ colorectal cancer: who really benefits from it? [J]. Surg Today, 2011, 41(2): 222229. |
46. | Nquyen HL, Hwang J. Treatment of metastatic colorectal cancer in the elderly [J]. Curr Treat Options Oncol, 2009, 10(56): 287295. |
47. | Power DG, Lichtman SM. Chemotherapy for the elderly patient with colorectal cancer [J]. Cancer J, 2010, 16(3): 241252. |
48. | Berretta M, Cappellani A, Fiorica F, et al. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study [J]. Arch Gerontol Geriatr, 2011, 52(1): 8993. |
49. | 丁丽, 武晓楠, 程刚. 奥沙利铂联合氟尿嘧啶和亚叶酸钙方案治疗70岁及以上转移性结直肠癌的疗效和安全性 [J]. 中华老年医学杂志, 2010, 30(2): 129132. |
50. | Suqimoto S, Katano K, Kanazawa A, et al. Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients [J]. J Exp Clin Cancer Res, 2009, 28: 109. |
51. | Sastre J, Aranda E, Massutí B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after firstline chemotherapy with oxaliplatinbased combinations: Comparative outcomes from the 03TTD01 phase Ⅲ study [J]. Crit Rev in Oncol Hematol, 2009, 70(2): 134144. |
52. | Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in firstline therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2 691 patients in randomized controlled trials [J]. J Clin Oncol, 2008, 26(9): 14431451. |
53. | Jackson NA, Barrueco J, SoufiMahjoubi R, et al. Comparing safety and efficacy of firstline irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostarcelecoxib study [J]. Cancer, 2009, 115(12): 26172629. |
54. | Vamvakas L, Athanasiadis A, Karampeazis A, et al. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase Ⅲ trial from the Hellenic Oncology Research Group (HORG) [J]. Crit Rev Oncol Hematol, 2010, 76(1): 6170. |
55. | Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as firstline treatment in elderly patients with metastatic colorectal cancer [J]. Br J Cancer, 2010, 102(10): 14681473. |
56. | Vrdoljak E, Omrˇcen T, Boban M, et al. Phase Ⅱ study of bevacizumab in combination with capecitabine as firstline treatment in elderly patients with metastatic colorectal cancer [J]. Anticancer Drugs, 2011, 22(2): 191197. |
57. | Hess GP, Wang PF, Quach D, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice [J]. J Oncol Pract, 2010, 6(6): 301307. |
58. | Cassidy J, Saltz LB, Giantonio BJ, et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies [J]. J Cancer Res Clin Oncol, 2010, 136(5): 737743. |
59. | Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study [J]. Oncology, 2010, 78(56): 329339. |
60. | Van Cutsem E, Rivera F, Berry S, et al. PD0005. Safety and efficacy of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer (MCRC): results from the BEAT observational cohort study [J]. Ann Oncol, 2009, 20(Supplement 7): vi18. |
61. | Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer [J]. Crit Rev Oncol Hematol, 2008, 67(3): 255262. |
62. | Fornaro L, Baldi GG, Masi G, et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status [J]. Crit Rev Oncol Hematol, 2010, doi: 10.1016/j.critrevonc. 2010. 06. 003. |
63. | Sastre J, Aranda E, Grávalos C, et al. Firstline singleagent cetuximab in elderly patients with metastatic colorectal cancer. A phase Ⅱ clinical and molecular study of the Spanish group for digestive tumor therapy (TTD) [J]. Crit Rev Oncol Hematol, 2011, 77(1): 7884. |
64. | Amado RG, Wolf M, Peeters M, et al. Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(10): 16261634. |
65. | Peeters M, Price TJ, Cervantes A, et al. Randomized phase Ⅲ study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2010, 28(31): 47064713. |
66. | Douillard JY, Siena S, Cassidy J, et al. Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study [J]. J Clin Oncol, 2010, 28(31): 46974705. |
67. | Mocellin S, Pasquali S, Nitti D. FluoropyrimidineHAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer [J]. Cochrane Database Syst Rev, 2009, (3): CD007823. |
68. | Faynsod M, Wagman LD, Longmate J, et al. Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy [J]. J Clin Oncol, 2005, 23(22): 48764880. |
69. | Hong K, McBride JD, Gerorgiades CS, et al. Salvage therapy for liver dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium90 radioembolization [J]. J Vasc Interv Radiol, 2009, 20(3): 360367. |
70. | 贾昌俊, 薛今琦, 戴朝六. 肝脏肿瘤原位组织消融治疗进展 [J]. 中国实用外科杂志, 2008, 28(8): 669671. |
71. | Abdalla EK. Commentary: Radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology [J]. Am J Surg, 2009, 197(6): 737739. |
72. | Tsoulfas G, Pramateftakis MG, Kanellos I. Surgical treatment of hepatic metastases from colorectal cancer [J]. World J Gastrointest Oncol, 2011, 3(1): 19. |
- 1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [J]. CA Cancer J Clin, 2010, 60(5): 277300.
- 2. 张思维, 雷正龙, 李光琳, 等. 中国肿瘤登记地区2006年肿瘤发病和死亡资料分析 [J]. 中国肿瘤, 2010, 19(6): 356365.
- 3. 中华医学会外科学分会胃肠外科学组、结直肠肛门外科学组, 中国抗癌协会大肠癌专业委员会. 结直肠癌肝转移诊断和治疗指南(V 2010) [J]. 中华胃肠外科杂志, 2010, 13(6): 457470.
- 4. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Colon Cancer. Version 3.2011. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
- 5. Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view [J]. Semin Liver Dis, 1984, 4(2): 170179.
- 6. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment [J]. Ann Surg, 1984, 199(5): 502508.
- 7. Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases [J]. Br J Surg, 2010, 97(7): 11101118.
- 8. Ito K, Govindarajan A, Ito H, et al. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century [J]. Cancer J, 2010, 16(2): 103110.
- 9. Tsim NC, Frampton AE, Habib NA, et al. Surgical treatment for liver cancer [J]. World J Gastroenterol, 2010, 16(8): 927933.
- 10. Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 19952007: an analysis of populationbased cancer registry data [J]. Lancet, 2011, 377(9760): 127138.
- 11. 中华人民共和国国家统计局. 2010年第六次全国人口普查主要数据公报(第1号). http://www.stats.gov.cn/tjfx/jdfx/t20110428_402722253.html.
- 12. 杜鹏, 翟振武, 陈卫. 中国人口老龄化百年发展趋势 [J]. 人口研究, 2005, 29(6): 9093.
- 13. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part Ⅰ [J]. Cancer J, 2005, 11(6): 449460.
- 14. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Senior Adult Oncology. Version 2.2011. http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf.
- 15. Pallis AG, Papamichael D, Audisio R, et al. EORTC Elderly Task Force experts’ opinion for the treatment of colon cancer in older patients [J]. Cancer Treat Rev, 2010, 36(1): 8390.
- 16. Brand MI, Saclarides TJ, Dobson HD, et al. Liver resection for colorectal cancer: liver metastases in the aged [J]. Ann Surg, 2000, 66(4): 412415, discussion 415416.
- 17. Zacharias T, Jaeck D, Oussoultzoglou E, et al. First and repeat resection of colorectal liver metastases in elderly patients [J]. Ann Surg, 2004, 240(5): 858865.
- 18. Nagano Y, Nojiri K, Matsuo K, et al. The impact of advanced age on hepatic resection of colorectal liver metastases [J]. J Am Coll surg, 2005, 201(4): 511516.
- 19. Menon KV, AlMukhtar A, Aldouri A, et al. Outcomes after major hepatectomy in elderly patients [J]. J Am Coll Surg, 2006, 203(5): 677683.
- 20. Figueras J, Ramos E, LopezBen S, et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? [J]. Clin Transl Oncol, 2007, 9(6): 392400.
- 21. Mazzoni G, Tocchi A, Miccini M, et al. Surgical treatment of liver metastases from colorectal cancer in elderly patients [J]. Int J Colorectal Dis, 2007, 22(1): 7783.
- 22. Wang X, Hershman DL, Abrams JA, et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis [J]. Br J Cancer, 2007, 97(12): 16061612.
- 23. de LiguoriCarino N, van Leeuwen BL, Ghaneh P, et al. Liver resection for colorectal liver metastases in older patients [J]. Crit Rev Oncol Hematol, 2008, 67(3): 273278.
- 24. Mann CD, Neal CP, Pattenden CJ, et al. Major resection of hepatic colorectal liver metastases in elderly patients - an aggressive approach is justified [J]. Eur J Surg Oncol, 2008, 34(4): 428432.
- 25. Bockhorn M, Sotiropoulos GC, Sgourakis G, et al. Major liver resections in the elderly-is an aggressive approach justified? [J]. Int J Colorectal Dis, 2009, 24(1): 8386.
- 26. Nojiri K, Nagano Y, Tanaka K, et al. Validity of hepatic resection of colorectal liver metastases in the elderly (75 years and older) [J]. Anticancer Res, 2009, 29(2): 583588.
- 27. Tamandl D, Gruenberger B, Herberger B, et al. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients [J]. J Surg Oncol, 2009, 100(5): 364371.
- 28. Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases: a national experience [J]. Cancer, 2009, 15(4): 752759.
- 29. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of longterm survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients [J]. Ann Surg, 2008, 247(1): 125135.
- 30. Reddy SK, Barbas AS, Turley RS, et al. Major liver resection in elderly patients: a multiinstitutional analysis [J]. J Am Coll Surg, 2011, 212(5): 787795.
- 31. 蔡三军. 结直肠癌肝转移的治疗现状 [J]. 中华胃肠外科杂志, 2009, 12(4): 430431.
- 32. Thelen A, Jonas S, Benckert C, et al. Simultaneous versus staged liver resection onf synchronous liver metastasis from colorectal cancer [J]. Int J Colorectal Dis, 2007, 22(10): 12691276.
- 33. 涂玉亮, 焦华波, 谭向东, 等. 70岁以上老年患者结直肠癌肝转移同步手术切除的临床分析 [J]. 中国急救复苏与灾害医学杂志, 2010, 5(8): 734736, 744.
- 34. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after twostage resection of advanced colorectal liver metastases: responsebased selection and complete resection define outcome [J]. J Clin Oncol, 2011, 29(8): 10831090.
- 35. Wicherts DA, Miller R, de Haas RJ, et al. Longterm results of twostage hepatectomy for irresectable colorectal cancer liver metastases [J]. Ann Surg, 2008, 248(6): 9941005.
- 36. Karoui M, Viqano L, Goyer P, et al. Combined firststage hepatectomy and colorectal resection in a twostage hepatectomy strategy for bilobar synchronous liver metastases [J]. Br J Surg, 2010, 97(9): 13541362.
- 37. Mohammad WM, Balaa FK. Surgical management of colorectal liver metastases [J]. Clin Colon Rectal Surg, 2009, 22(4): 225232.
- 38. de Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastases: results from an international multiinstitutional analysis [J]. J Gastrointest Surg, 2009, 13(12): 21412151.
- 39. Sa Cunha A, Laurent C, Rault A, et al. A second liver resection due to recurrent colorectal liver metastases [J]. Arch Surg, 2007, 142(12): 11441149.
- 40. de Liquori Carino N, van Leeuwen BL, Ghaneh P, et al. Liver resection for colorectal liver metastases in older patients [J]. Crit Rev Oncol Hematol, 2008, 67(3): 273278.
- 41. Adam R, Bhanqui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? [J]. Ann Surg, 2010, 252(5): 774787.
- 42. Nordlinger B, Van Cutsem E, Rouqier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group [J]. Eur J Cancer, 2007, 43(14): 20372045.
- 43. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage Ⅳ colorectal cancer receiving combination chemotherapy without surgery as initial treatment [J]. J Clin Oncol, 2009, 27(20): 33793384.
- 44. Costi R, Di Mauro D, Giordano P, et al. Impact of palliative chemotherapy and surgery on management of stage Ⅳ incurable colorectal cancer [J]. Ann Surg Oncol, 2010, 17(2): 432440.
- 45. Costi R, Di Mauro D, Veronesi L, et al. Elective palliative resection of incurable stage Ⅳ colorectal cancer: who really benefits from it? [J]. Surg Today, 2011, 41(2): 222229.
- 46. Nquyen HL, Hwang J. Treatment of metastatic colorectal cancer in the elderly [J]. Curr Treat Options Oncol, 2009, 10(56): 287295.
- 47. Power DG, Lichtman SM. Chemotherapy for the elderly patient with colorectal cancer [J]. Cancer J, 2010, 16(3): 241252.
- 48. Berretta M, Cappellani A, Fiorica F, et al. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study [J]. Arch Gerontol Geriatr, 2011, 52(1): 8993.
- 49. 丁丽, 武晓楠, 程刚. 奥沙利铂联合氟尿嘧啶和亚叶酸钙方案治疗70岁及以上转移性结直肠癌的疗效和安全性 [J]. 中华老年医学杂志, 2010, 30(2): 129132.
- 50. Suqimoto S, Katano K, Kanazawa A, et al. Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients [J]. J Exp Clin Cancer Res, 2009, 28: 109.
- 51. Sastre J, Aranda E, Massutí B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after firstline chemotherapy with oxaliplatinbased combinations: Comparative outcomes from the 03TTD01 phase Ⅲ study [J]. Crit Rev in Oncol Hematol, 2009, 70(2): 134144.
- 52. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in firstline therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2 691 patients in randomized controlled trials [J]. J Clin Oncol, 2008, 26(9): 14431451.
- 53. Jackson NA, Barrueco J, SoufiMahjoubi R, et al. Comparing safety and efficacy of firstline irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostarcelecoxib study [J]. Cancer, 2009, 115(12): 26172629.
- 54. Vamvakas L, Athanasiadis A, Karampeazis A, et al. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase Ⅲ trial from the Hellenic Oncology Research Group (HORG) [J]. Crit Rev Oncol Hematol, 2010, 76(1): 6170.
- 55. Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as firstline treatment in elderly patients with metastatic colorectal cancer [J]. Br J Cancer, 2010, 102(10): 14681473.
- 56. Vrdoljak E, Omrˇcen T, Boban M, et al. Phase Ⅱ study of bevacizumab in combination with capecitabine as firstline treatment in elderly patients with metastatic colorectal cancer [J]. Anticancer Drugs, 2011, 22(2): 191197.
- 57. Hess GP, Wang PF, Quach D, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice [J]. J Oncol Pract, 2010, 6(6): 301307.
- 58. Cassidy J, Saltz LB, Giantonio BJ, et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies [J]. J Cancer Res Clin Oncol, 2010, 136(5): 737743.
- 59. Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study [J]. Oncology, 2010, 78(56): 329339.
- 60. Van Cutsem E, Rivera F, Berry S, et al. PD0005. Safety and efficacy of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer (MCRC): results from the BEAT observational cohort study [J]. Ann Oncol, 2009, 20(Supplement 7): vi18.
- 61. Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer [J]. Crit Rev Oncol Hematol, 2008, 67(3): 255262.
- 62. Fornaro L, Baldi GG, Masi G, et al. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status [J]. Crit Rev Oncol Hematol, 2010, doi: 10.1016/j.critrevonc. 2010. 06. 003.
- 63. Sastre J, Aranda E, Grávalos C, et al. Firstline singleagent cetuximab in elderly patients with metastatic colorectal cancer. A phase Ⅱ clinical and molecular study of the Spanish group for digestive tumor therapy (TTD) [J]. Crit Rev Oncol Hematol, 2011, 77(1): 7884.
- 64. Amado RG, Wolf M, Peeters M, et al. Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(10): 16261634.
- 65. Peeters M, Price TJ, Cervantes A, et al. Randomized phase Ⅲ study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2010, 28(31): 47064713.
- 66. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study [J]. J Clin Oncol, 2010, 28(31): 46974705.
- 67. Mocellin S, Pasquali S, Nitti D. FluoropyrimidineHAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer [J]. Cochrane Database Syst Rev, 2009, (3): CD007823.
- 68. Faynsod M, Wagman LD, Longmate J, et al. Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy [J]. J Clin Oncol, 2005, 23(22): 48764880.
- 69. Hong K, McBride JD, Gerorgiades CS, et al. Salvage therapy for liver dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium90 radioembolization [J]. J Vasc Interv Radiol, 2009, 20(3): 360367.
- 70. 贾昌俊, 薛今琦, 戴朝六. 肝脏肿瘤原位组织消融治疗进展 [J]. 中国实用外科杂志, 2008, 28(8): 669671.
- 71. Abdalla EK. Commentary: Radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology [J]. Am J Surg, 2009, 197(6): 737739.
- 72. Tsoulfas G, Pramateftakis MG, Kanellos I. Surgical treatment of hepatic metastases from colorectal cancer [J]. World J Gastrointest Oncol, 2011, 3(1): 19.